APA (7th ed.) Citation

KH, C., P, C., T, S., S, C., H, Z., A, G., . . . N, T. (2026). Consolidation enfortumab vedotin and pembrolizumab after cisplatin induction in metastatic urothelial cancer: Outcomes of complete response and bladder preservation. The Journal of international medical research, 54(3), 3000605261430450. https://doi.org/10.1177/03000605261430450

Chicago Style (17th ed.) Citation

KH, Chan, et al. "Consolidation Enfortumab Vedotin and Pembrolizumab After Cisplatin Induction in Metastatic Urothelial Cancer: Outcomes of Complete Response and Bladder Preservation." The Journal of International Medical Research 54, no. 3 (2026): 3000605261430450. https://doi.org/10.1177/03000605261430450.

MLA (9th ed.) Citation

KH, Chan, et al. "Consolidation Enfortumab Vedotin and Pembrolizumab After Cisplatin Induction in Metastatic Urothelial Cancer: Outcomes of Complete Response and Bladder Preservation." The Journal of International Medical Research, vol. 54, no. 3, 2026, p. 3000605261430450, https://doi.org/10.1177/03000605261430450.